Systemic inflammatory and neurodegenerative pathways (N/A)

Systemic inflammatory and neurodegenerative pathways represent the integrated physiological and pathological processes where peripheral immune activation influences the central nervous system's health and disease progression (Perry et al., 2007, Nature Reviews Immunology). Chronic systemic inflammation, driven by factors such as aging, infection, or metabolic syndrome, leads to the release of pro-inflammatory cytokines that can cross or weaken the blood-brain barrier (Banks, 2005, Journal of NeuroVirology). Once in the brain, these signals activate microglia and astrocytes, creating a self-perpetuating cycle of neuroinflammation that accelerates neuronal death and the accumulation of toxic protein aggregates (Cunningham, 2013, Nature Reviews Rheumatology). This crosstalk is a hallmark of major neurodegenerative conditions like Alzheimer's and Parkinson's diseases, where systemic comorbidities often correlate with faster cognitive decline (Holmes et al., 2009, Neurology). Therapeutic interventions aimed at these pathways seek to decouple peripheral triggers from central responses, often by targeting specific cytokines or stabilizing the neurovascular unit. Consequently, these pathways are a major focus for developing disease-modifying therapies that address the systemic nature of brain disorders (Ransohoff, 2016, Science).

Other names

Neuroinflammation-systemic inflammation axisSystemic-to-brain inflammatory signalingPeripheral-central immune crosstalkSystemic-neurodegenerative interactome

Modulation of systemic pro-inflammatory cytokine levels (e.g., TNF-alpha, IL-6, IL-1 beta) and stabilization of the neurovascular unit to prevent peripheral immune signals from triggering chronic microglial activation and subsequent neuronal loss.